Antag Therapeutics

Copenhagen, DK · 3 known investors

Antag Therapeutics develops GIP receptor antagonist therapies for obesity, diabetes, and overweight patients. The company's lead candidate, AT-7687, is a clinical-stage peptide designed to block dysfunctional biological pathways contributing to fat storage and metabolic dysfunction, offering an alternative treatment approach with improved tolerability.